Introduction
Macrophage-derived TNFa is a cytokine that is increasingly recognized as a central mediator in a wide spectrum of physio-logic and immune functions. This molecule manifests a diverse range of biological effects, including tumoricidal activity and the wasting associated with chronic disease (1) , and is assumed to serve as a proximal mediator in the evolution of septic shock (2) . Giving TNFa to animals causes a syndrome similar to septic shock and induces acute lung injury with respiratory insufficiency and death (2) . The mechanisms by which TNFa causes its effects have not been totally explained, but it is known that it can increase lung capillary permeability, has chemotactic properties for inflammatory cells, and is capable of activating neutrophils and endothelial cells (2) .
Alterations in type II pneumocyte function, including surfactant biosynthesis, may have a significant role in the pathogenesis of sepsis-induced lung injury (3, 4) . In addition to its endothelium-activating properties, TNFa can contribute to the physiopathology of adult respiratory distress syndrome (ARDS)' also by modifying the surfactant composition. In fact, TNFa has been found to be located principally within type II pneumocytes in both early and late stages of human ARDS (5) .
The signal transduction mechanisms by which TNFa exerts its varied biological effects have not been fully elucidated. A number of findings suggest that the stimulation of prostaglandin synthesis may contribute to some of its biological effects. TNFa induces PGI2 production in endothelial cells and PGE2 production in human synovial cells and dermal fibroblasts (6) . Furthermore, the release of arachidonic acid from phospholipids appears to be a critical element in the signaling pathway used by TNFa (7) . Cyclooxygenase inhibitors have been shown to reduce the toxicity associated with TNFa administration (8) , and there are also interesting reports of enhanced survival and improved physiology afforded by cyclooxygenase inhibitors in models of sepsis (9) and ARDS (8, 9) . The role of lipoxygenase products in mediating cytokine effects is less clear (10) ; nevertheless, maximal protection against TNFa-mediated in vitro toxicity seems to be afforded when both cyclo-and lipoxygenase inhibitors are used together. Despite these data, the precise role of the arachidonic acid metabolites in the mediation of the TNFa-induced lung injury remains unknown.
We designed this study to determine the effect of TNFa on phospholipid synthesis by isolated type II alveolar cells and to characterize the role of arachidonate metabolites on this effect. This was done by culturing type H human pneumocytes with TNFa in the presence and absence of indomethacin (cyclooxygenase inhibitor), nordihydroguaiaretic acid (NDGA) (lipoxygenase inhibitor), and/or prostaglandins.
1. Abbreviations used in this paper: ARDS, adult respiratory distress syndrome; DPPC, disaturated phosphatidylcholine; LPC, lysophosphatidylcholine; NDGA, nordihydroguaiaretic acid; PA, phosphatidic acid; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PGL, phosphatidylglycerol; PI, phosphatidylinositol; PL, phospholipase; PPI, polyphosphoinositides; PTXF, pentoxifylline; SF, sphingomyelin.
On the other hand, recent studies have shown that pentoxifylline (PTXF), an inhibitor of phosphodiesterase, reduces lung damage in septic animals and is capable of improving the hemodynamic manifestations and survival rate in experimental models of septic shock ( 11) . In this study, we also analyzed the influence of PTXF on the TNFa effect.
To obtain the lung tissue used for isolating pneumocytes, we used previously healthy multiple organ donors and lung cancer patients and studied the possible differences between the two groups. 
Methods
Patients and lung tissue procurement. Human lung tissue was obtained from portions of the right lower lobe from cadaveric multiple organ donors and from the nontumoral portion of the surgically excised right lower lobe from lung cancer patients.
The donor group was made up of 14 male patients diagnosed with brain death secondary to cranial trauma, with < 72 h of mechanical ventilation and with no radiological signs of lung infiltration. After harvesting the organs that were going to be used for transplantation, a right lower lobectomy was performed, and the pulmonary lobe was placed in cold saline solution.
The cancer group was made up of 11 male patients that underwent right pneumonectomy for squamous cell lung cancer that did not significantly affect the lower lobe. Lungs were placed immediately in cold saline, and the portion of the basal lobe farthest from the tumor was excised, washed, and then stored in cold saline solution.
The cadaveric as well as the cancer patient groups were operated on in our hospital institution. All donors and cancer patients had antecedent of recent tobacco smoking. The 27 "orcein-elastin" units/ml elastase, 10 jig/ml DNase, 0.5 mg/ml trypsin, and 0.5 mg/ml (2.7 IU/mg) collagenase.
The time period between lobectomy and the beginning of isolation was never > 3 h. The lung tissue was rinsed with solution I and minced into small pieces ( 1-3 mm), which were then washed extensively with the same solution to remove blood cells as much as possible. Subsequently, the portions were digested by two consecutive exposures, of 30 min each, to solution H in a 370C shaking water bath. The tissue digestion was terminated by the addition of fetal calf serum at 40C, and the resulting cellular suspension was filtered through two nylon meshes (200 and 20 jsm, respectively) and centrifuged at 250 g for 10 min.
After removing the supernatant, the pellets were resuspended in RPMI 1640 medium, added to 75-cm2 flasks, precoated with fetal calf serum, and cultured in a 5% C02/95% 02 air incubator at 370C for 90 min, during which most of the alveolar macrophages adhered to the plastic. After 90 min, the nonadherent cells were removed, centrifuged (250 g for 10 min), and resuspended in solution I. For further purification, the suspension was applied to a Percoll gradient established by centrifuging the combination of Percoll with phosphate-buffered saline (25 mmol/ liter NaH2PO4, 300 mmol/liter NaCl, pH 7.4), in a 6:7 (vol/vol) ratio for 10 min at 20,000 g (12) . Cells were counted in a standard hemacytometer. plates of Silica Gel 60 (20 x 20 cm; E. Merck) previously activated for 1 h at 110TC. Lipid separation was performed by unidimensional chromatography with two solvent systems, as described previously in detail (14) . After the plates had been sprayed with 2 '7 '-dichlorofluorescein, the following spots were detected under ultraviolet light and identified with adequate markers: polyphosphoinositides (PPI) (origin), lysophosphatidylcholine (LPC), sphingomyelin (SF), PC, phosphatidylserine and phosphatidylinositol (PI), phosphatidylethanolamine (PE), phosphatidic acid (PA), and phosphatidylglycerol (PGL). Each spot was scraped off into a scintillation vial, and its radioactivity was measured. To exclude any "carry-through" of unincorporated label, experiments in which label was added just before freezing cells were used as control.
In experiments done separately, the effect of TNFa and PTXF on disaturated phosphatidylcholine (DPPC) synthesis was examined. To do this, we reacted the total PC fraction with osmium tetroxide in carbon tetrachloride and then separated the saturated species of PC from the unsaturated ones by thin-layer chromatography on silica-gel plates impregnated with boric acid, using chloroform:methanol:ammonium hydrochloride:water (75:25:1:2). Different amounts of a standard DPPC solution were spotted directly onto the plates. To estimate the recovery of disaturated species from the initial sample, we repeated the procedure with samples of radioactive saturated PC. The recovery was 78.2±5.1% (n = 5).
A frozen aliquot of the cellular suspension was stored for the determination of proteins, which was done by the Coomassie brilliant blue spectrophotometric method.
Chromium-Si release assays. To exclude the possibility of a nonspecific TNFa effect due to cytotoxicity, we measured cell lysis by a standard chromium-51 release assay. Cells were labeled by incubation at 37°C in 150 ,ul RPMI 1640 medium/well with 2 pCi 51Cr-labeled sodium chromate for 24 h and then washed four times. The TNFa was diluted in RPMI 1640 medium and added to the cell culture; the plates were incubated at 37°C for 24 h, after which an aliquot (100 ,1) of the medium was collected and counted in a gamma counter. Specific cell lysis was calculated as 100 x (test medium cpm -spontaneous cpm/ total cpm -spontaneous cpm). Spontaneous release of chromium-51 measured in wells incubated in RPMI 1640 medium alone was < 20% of total chromium-51 release, which was measured by dissolving the cells in 4% Triton X-100 for 6 h. In the presence of 100 ng/ml TNFa, the cell lysis (percentage of chromium-51 release above spontaneous release) was insignificant. 30 and 60 min, except for PC fraction which showed a tendency to reach isotopic equilibrium between 120 and 180 min.
After 120 min of incubation, TNFa decreased, in a dosedependent fashion, the synthesis of PC by type H pneumocytes isolated from donors (Fig. 2) . Maximal effect was apparently reached at 200 ng/ml.
When the effect of cancer on phospholipid metabolism was investigated, we found that the basal PC synthesis was higher in the donor group than in the malignant group. Cancer also decreased LPC and PGL labeling, while the incorporation of labeled glucose into the other phospholipid fractions was similar in both groups (Fig. 3 ).
In the presence of 100 ng/ml of TNFa, the incorporation of D-[U-14C ] glucose into PC was reduced significantly in both donor and cancer groups (Fig. 4) ; in contrast, no changes were observed in the labeling of the other phospholipid fractions investigated. PTXF completely blocked the effect of TNFa in pneumocytes from the donor group and increased PC synthesis in those from the malignant group (both with and without TNFa) to a value similar to that in pneumocytes from the donor group in the absence of additives (Fig. 4) .
To investigate whether the TNFa-induced decrease in PC synthesis was mediated by prostaglandins, we first studied the effect of PGEI and PGE2. As occurred with TNFa, both PGEI and PGE2 reduced the incorporation of D-[U-"C ]glucose into PC in both donor and cancer groups (Fig. 5 A) , and this effect was not additive with that of TNFa (Fig. 5 B) . However, in contrast with what happened with the TNFa effect, PTXF just partially reversed the prostaglandin effect (Fig. 4) .
We next sought to investigate the effect of cyclooxygenase and lipoxygenase blockade on PC synthesis. Fig. 6 B shows that indomethacin was able to completely block the cytokineinduced decrease in labeled glucose incorporation into PC by type H pneumocytes from the malignant group and to attenuate the inhibitory effect of TNFa in those from the donor group. Administration of NDGA had a similar effect (Fig. 6 B) . Neither indomethacin nor NDGA modified PC synthesis in the absence of TNFa (Fig. 6 A) .
After 2 h of incubation, the radioactivity in DPPC comprised about 58% of the label incorporated into total PC in both donor and cancer groups. In the presence of TNFa, PTXF, or both, the results were similar to those observed for total PC (data not shown).
No correlation was found between patient age and PC synthesis when studied separately in the donor (r = -0.03, P = 0.92) and cancer (r = -0.30, P = 0.36) group.
Discussion
There is a growing body of evidence to suggest that TNFa and other cytokines mediate endotoxemia and ARDS (2) . TNFa is secreted by alveolar macrophages after endotoxin exposure (2), and, among other cellular types, type II pneumocytes may represent a target for this cytokine (5) . Alteration in the synthesis or composition of surfactant may have an important role in the pathogenesis of ARDS (3, 4) , and a close correlation between alterations in the lipid composition of bronchoalveolar lavage fluid and a predisposition to ARDS has been demonstrated in polytraumatized patients (15) .
This work shows that TNFa has an inhibitory effect on the de novo synthesis of PC, the main component of pulmonary surfactant. This finding agrees with previous in vivo results (2, 16) and suggests that TNFa participates in the physiopathology of ARDS by this mechanism. Dipalmitoylphosphatidylcholine is specific to surfactant, while PC itself is not; to test the assumption that the total PC was an adequate marker of its disaturated fraction in our system, we studied the effect of TNFa and PTXF on DPPC synthesis in separate experiments, observing a complete parallelism in the synthesis of both fractions.
The lower basal synthesis rate of PC found in the cancer group could, hypothetically, be also mediated in vivo by TNFa. It is known that lung cancer cells can secrete an abundance of growth factors and cytokines, including TNFa, without prior exogenous stimulation (17) . Furthermore, the alveolar macrophages of lung cancer patients seem to be primed to produce Figure 4 . Effect of PTXF (100 jg/ml) alone, and of TNFa (100 ng/ ml), PGE2 (10-7 mol/liter), and PGE, ( 10-7 mol/liter), with or without PTXF, on the synthesis of PC by type H pneumocytes isolated from normal (Donor, n = 14) and cancer-bearing lungs (Cancer, n = 11). *fP < 0.01 and **P vs control.
great quantities of TNFa after being activated (18) . On the other hand, there is recent evidence that the production and effects of TNFa are generally confined to organic compartments ( 19) . Therefore, in cancer patients the metabolic consequences of TNFa could be more apparent within the tumor-bearing organ than elsewhere. Beneficial effects of PTXF have been reported in experimental models of septic shock and ARDS (11). This substance decreased the production of TNFa by activated macrophages (20) and has proven capable of blocking some effects of TNFa on the endothelium (21) . Our results show clearly that PTXF can also block the inhibitory effect of TNFa on the synthesis of PC. The greatest effect of PTXF was observed when pneumocytes from cancer patients were used. In this condition, PTXF was not only capable of blocking the effect of TNFa, but it also increased the production of PC in the absence of the cytokine, since the final PC levels were similar to those found in pneumocytes from donors in the absence of TNFa. This suggests that the mechanism of functional impairment induced by cancer and by TNFa could be common to both situations, therefore supporting the hypothesis that some of the alterations observed in lung cancer could be due to chronic paracrine exposure to TNFa (1, 22) . The above finding also makes unlikely the possibility that the reduction in basal PC synthesis observed in the cancer group pneumocytes could be due to cell damage secondary to the different harvesting procedure or any other variable.
Considerable efforts have been devoted to clarify the postreceptor mechanism of TNFa. However, the available data are difficult to interpret, since they have been obtained on a variety of cells types and animal species that respond differently to TNFa. Our results show that prostaglandins have a role in mediating the TNFa inhibitory effect. This finding is in line with previous reports which suggest that the release of arachidonic acid from phospholipids is a critical element in the signaling pathway used by TNFa and is essential to the rapid cytotoxic Effect of Tumor Necrosis Factor-a on Surfactant Production response elicited by TNFa (7). In fact, TNFa has been shown to induce expression of prostaglandin endoperoxide synthase, a key enzyme in the formation of prostaglandins, in both neutrophils and endothelial cells (23) . Cyclooxygenase inhibitors improve physiologic parameters and survival after endotoxin (9) or TNFa (8) challenge. However, it is clear that not all of the physiologic changes of endotoxemia seen in vivo are due to cyclooxygenase products. Similarly, it is apparent that not all the effects of TNFa are mediated by arachidonate metabolites (9) . In concordance with this concept, our data suggest that the mechanism by which TNFa inhibits PC synthesis is only partially mediated by prostaglandins. In fact, the TNFa effect on donor type II pneumocytes seems to have at least two components, one of them being prostaglandin-mediated and suitable to indomethacin blocking. In this latter component, metabolites from both the cyclo-and the lipoxygenase pathways are implicated. In type II pneumocytes from the cancer group, however, the TNFa effect appears to be mediated exclusively by arachidonic acid metabolites. It is known that TNFa affects fat metabolism in a much greater way in healthy humans than in patients with disseminated neoplasia. It is believed that this behavior is because of a partial tolerance (1) to TNFa in cancer patients, secondary to their prolonged exposure to this cytokine (22) . In the face of these observations, it could be hypothesized that cells from the cancer group have acquired tolerance to the prostaglandin-independent TNFa effects.
Several lines of evidence suggest the importance of phospholipases in the mechanism by which TNFa exerts its actions. In addition to their well known arachidonate-releasing action, these enzymes can contribute to the TNFa effect on pneumocytes by other mechanisms. In the last few years, it has been observed that an increase in the turnover of PC is an early event in the action of diverse agonists. Diverse cell types can synthesize and secrete group II phospholipase (PL) A2 upon stimulation in vitro with cytokines (24) , and several distinct forms of PLA2 are present in the lung (25) PTXF increases intracellular levels of cAMP by inhibiting phosphodiesterase activity. This increase in cAMP seems to play a role in decreasing lung injury ( 11) . Additionally, it has been shown that PTXF is a potent inhibitor of the formation of free radicals (29) . Our finding that PTXF was not able to completely revert the prostaglandin effect, in contrast with that of TNFa, may have an explanation in the reported effect of PTXF as an inhibitor of both PLA2 and PLC (30) 
